INSIGHTS ON EMERGING CAR T THERAPIES

Researchers suspect that ablation of the transcription factor Blimp-1 might address the lack of durable efficacy observed with chimeric antigen receptor T-cells (CAR-T) targeting B-cell maturation...

For over 30 years, autologous stem cell transplantation (ASCT) has remained a key component of first-line treatment for multiple myeloma (MM).

Research suggests odronextamab is beneficial for individuals with relapsed/refractory diffuse large B-cell lymphoma whose condition worsens after chimeric antigen receptor T-cell (CAR T) therapy.

Researchers at Boston Children's Hospital, Dana-Farber Cancer Institute, and Harvard Medical School have developed an innovative regulatory T cell (Treg)-based therapy to address challenges in...

Scientists believe they have identified a way to circumvent the antigen heterogeneity that has challenged chimeric antigen receptor (CAR) T cell treatment in the setting of acute myeloid leukemia...

Researchers from the University of Wisconsin, Cornell, and a consortium of other institutions conducted a retrospective analysis on CD19-directed Chimeric Antigen Receptor T-cell (CAR T-cell)...